ATE405295T1 - Verbesserte raav-expressionssysteme für die genetische modifikation spezifischer capsidproteine - Google Patents
Verbesserte raav-expressionssysteme für die genetische modifikation spezifischer capsidproteineInfo
- Publication number
- ATE405295T1 ATE405295T1 AT03786493T AT03786493T ATE405295T1 AT E405295 T1 ATE405295 T1 AT E405295T1 AT 03786493 T AT03786493 T AT 03786493T AT 03786493 T AT03786493 T AT 03786493T AT E405295 T1 ATE405295 T1 AT E405295T1
- Authority
- AT
- Austria
- Prior art keywords
- vectors
- expression systems
- raav
- genetic modification
- methods
- Prior art date
Links
- 108090000565 Capsid Proteins Proteins 0.000 title 1
- 238000012239 gene modification Methods 0.000 title 1
- 230000005017 genetic modification Effects 0.000 title 1
- 235000013617 genetically modified food Nutrition 0.000 title 1
- 238000000034 method Methods 0.000 abstract 3
- 239000013598 vector Substances 0.000 abstract 3
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 108020000948 Antisense Oligonucleotides Proteins 0.000 abstract 1
- 102000053642 Catalytic RNA Human genes 0.000 abstract 1
- 108090000994 Catalytic RNA Proteins 0.000 abstract 1
- 229920002971 Heparan sulfate Polymers 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 241000700605 Viruses Species 0.000 abstract 1
- 239000000074 antisense oligonucleotide Substances 0.000 abstract 1
- 238000012230 antisense oligonucleotides Methods 0.000 abstract 1
- 238000001476 gene delivery Methods 0.000 abstract 1
- 229920000669 heparin Polymers 0.000 abstract 1
- 229960002897 heparin Drugs 0.000 abstract 1
- -1 host cells Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 210000000056 organ Anatomy 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 239000013608 rAAV vector Substances 0.000 abstract 1
- 108091092562 ribozyme Proteins 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 210000002845 virion Anatomy 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14145—Special targeting system for viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
- C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
- C12N2810/858—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from apolipopeptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Virology (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37731502P | 2002-05-01 | 2002-05-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE405295T1 true ATE405295T1 (de) | 2008-09-15 |
Family
ID=32030574
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03786493T ATE405295T1 (de) | 2002-05-01 | 2003-05-01 | Verbesserte raav-expressionssysteme für die genetische modifikation spezifischer capsidproteine |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US8802080B2 (de) |
| EP (1) | EP1496944B1 (de) |
| AT (1) | ATE405295T1 (de) |
| AU (1) | AU2003295312B2 (de) |
| CA (1) | CA2483624A1 (de) |
| DE (1) | DE60323078D1 (de) |
| DK (1) | DK1496944T3 (de) |
| NZ (2) | NZ536274A (de) |
| SI (1) | SI1496944T1 (de) |
| WO (1) | WO2004027019A2 (de) |
Families Citing this family (84)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060093589A1 (en) * | 2004-02-19 | 2006-05-04 | Warrington Kenneth H | Vp2-modified raav vector compositions and uses therefor |
| DE60323078D1 (de) | 2002-05-01 | 2008-10-02 | Univ Florida | Verbesserte raav-expressionssysteme für die genetische modifikation spezifischer capsidproteine |
| US20040179028A1 (en) * | 2003-03-12 | 2004-09-16 | Fuji Photo Film Co., Ltd. | Pixel defect correcting method, color mura correcting method and image display device |
| EP1618201A1 (de) * | 2003-05-01 | 2006-01-25 | University of Florida Research Foundation, Inc. | Vp2-modifizierte raav-vektoren und verwendungen davon |
| EP1486567A1 (de) | 2003-06-11 | 2004-12-15 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Verbesserter Adeno-assoziierter Virus (AAV)-Vektor für Gentherapie |
| ES2329636B2 (es) | 2006-02-17 | 2010-07-26 | Universitat De Valencia, Estudi General (Participa Con El 70%) | Uso del factor pedf para inducir la auto-renovacion de celulas madre. |
| US9725485B2 (en) | 2012-05-15 | 2017-08-08 | University Of Florida Research Foundation, Inc. | AAV vectors with high transduction efficiency and uses thereof for gene therapy |
| PL2191001T4 (pl) | 2007-04-09 | 2017-01-31 | University Of Florida Research Foundation, Inc. | Kompozycje wektora RAAV mające białka kapsydu zmodyfikowane tyrozyną i sposoby ich zastosowania |
| US9611302B2 (en) | 2007-04-09 | 2017-04-04 | University Of Florida Research Foundation, Inc. | High-transduction-efficiency RAAV vectors, compositions, and methods of use |
| JP2011512417A (ja) * | 2008-02-20 | 2011-04-21 | ジェンザイム・コーポレーション | 血管形成の阻害 |
| CA2762118A1 (en) | 2008-05-20 | 2010-01-28 | Eos Neuroscience, Inc. | Vectors for delivery of light-sensitive proteins and methods of use |
| WO2010093784A2 (en) | 2009-02-11 | 2010-08-19 | The University Of North Carolina At Chapel Hill | Modified virus vectors and methods of making and using the same |
| DK2403867T3 (da) | 2009-03-04 | 2019-08-12 | Deutsches Krebsforsch | Assembly activating protein (aap) og dets anvendelse til fremstilling af parvoviruspartikler hovedsageligt bestående af vp3 |
| US9783601B2 (en) | 2010-12-01 | 2017-10-10 | Alderbio Holdings Llc | Methods of preventing inflammation and treating pain using anti-NGF compositions |
| US9067988B2 (en) | 2010-12-01 | 2015-06-30 | Alderbio Holdings Llc | Methods of preventing or treating pain using anti-NGF antibodies |
| US11214610B2 (en) | 2010-12-01 | 2022-01-04 | H. Lundbeck A/S | High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris |
| US9884909B2 (en) | 2010-12-01 | 2018-02-06 | Alderbio Holdings Llc | Anti-NGF compositions and use thereof |
| US9539324B2 (en) | 2010-12-01 | 2017-01-10 | Alderbio Holdings, Llc | Methods of preventing inflammation and treating pain using anti-NGF compositions |
| US9078878B2 (en) | 2010-12-01 | 2015-07-14 | Alderbio Holdings Llc | Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75 |
| EP2500434A1 (de) * | 2011-03-12 | 2012-09-19 | Association Institut de Myologie | Capsidfreie AAV-Vektoren, Zusammensetzungen und Verfahren zur Vektorherstellung und Genlieferung |
| HK1202434A1 (en) * | 2011-11-22 | 2015-10-02 | The Children's Hospital Of Philadelphia | Virus vectors for highly efficient transgene delivery |
| US10294281B2 (en) | 2012-05-15 | 2019-05-21 | University Of Florida Research Foundation, Incorporated | High-transduction-efficiency rAAV vectors, compositions, and methods of use |
| US12358954B2 (en) | 2012-05-15 | 2025-07-15 | University Of Florida Research Foundation, Incorporated | Capsid-modified rAAV vector compositions and methods therefor |
| HUE047996T2 (hu) | 2013-07-22 | 2020-05-28 | Childrens Hospital Philadelphia | AAV variáns és készítmények, eljárások és alkalmazások sejtekbe, szervekbe és szövetekbe történõ géntranszferhez |
| CN104592364B (zh) * | 2013-10-30 | 2018-05-01 | 北京大学 | 定点突变和定点修饰的腺相关病毒、其制备方法及应用 |
| CN105792914A (zh) * | 2013-12-06 | 2016-07-20 | 庄信万丰股份有限公司 | 冷启动催化剂和其在排气系统中的用途 |
| GB201403684D0 (en) | 2014-03-03 | 2014-04-16 | King S College London | Vector |
| WO2015134643A1 (en) | 2014-03-04 | 2015-09-11 | University Of Florida Research Foundation, Inc. | Improved raav vectors and methods for transduction of photoreceptors and rpe cells |
| KR102863726B1 (ko) * | 2014-05-02 | 2025-09-25 | 젠자임 코포레이션 | 망막 및 cns 유전자 요법을 위한 aav 벡터 |
| US10577627B2 (en) | 2014-06-09 | 2020-03-03 | Voyager Therapeutics, Inc. | Chimeric capsids |
| EP3800260A1 (de) * | 2014-09-24 | 2021-04-07 | City of Hope | Adeno-assoziierte virusvektorvarianten für hocheffiziente genomeditierung und verfahren dafür |
| MX2017005834A (es) | 2014-11-05 | 2017-11-17 | Voyager Therapeutics Inc | Polinucleotidos aad para el tratamiento de la enfermedad de parkinson. |
| GB201420139D0 (en) | 2014-11-12 | 2014-12-24 | Ucl Business Plc | Factor IX gene therapy |
| CN107109407A (zh) | 2014-11-14 | 2017-08-29 | 沃雅戈治疗公司 | 治疗肌萎缩性侧索硬化(als)的组合物和方法 |
| SG10202001102XA (en) | 2014-11-14 | 2020-03-30 | Voyager Therapeutics Inc | Modulatory polynucleotides |
| EP3031820A1 (de) | 2014-12-08 | 2016-06-15 | Life Science Inkubator | JC Polyomavirus virus-ähnliche Partikeln (VLP) mit einem Targeting-Peptid |
| WO2016094783A1 (en) | 2014-12-12 | 2016-06-16 | Voyager Therapeutics, Inc. | Compositions and methods for the production of scaav |
| US20180030096A1 (en) | 2015-02-03 | 2018-02-01 | University Of Florida Research Foundation, Inc. | Recombinant aav1, aav5, and aav6 capsid mutants and uses thereof |
| WO2016133917A1 (en) | 2015-02-16 | 2016-08-25 | University Of Florida Research Foundation | Raav vector compositions, methods for targeting vascular endothelial cells and use in treatment of type i diabetes |
| US10081659B2 (en) | 2015-04-06 | 2018-09-25 | The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services | Adeno-associated vectors for enhanced transduction and reduced immunogenicity |
| WO2016186772A2 (en) | 2015-05-16 | 2016-11-24 | Genzyme Corporation | Gene editing of deep intronic mutations |
| PE20180675A1 (es) | 2015-06-23 | 2018-04-19 | Childrens Hospital Philadelphia | Factor ix modificado, y composiciones, metodos y usos para la transferencia de genes a celulas, organos y tejidos |
| ES2865487T3 (es) | 2015-09-28 | 2021-10-15 | Univ North Carolina Chapel Hill | Métodos y composiciones para vectores virales que evaden los anticuerpos |
| US20190071681A1 (en) * | 2016-02-26 | 2019-03-07 | University Of Florida Research Foundation, Incorporated | Aav heparin mutants that display significantly improved eye and brain transduction |
| EP3448874A4 (de) | 2016-04-29 | 2020-04-22 | Voyager Therapeutics, Inc. | Zusammensetzungen zur behandlung einer erkrankung |
| EP3448987A4 (de) | 2016-04-29 | 2020-05-27 | Voyager Therapeutics, Inc. | Zusammensetzungen zur behandlung einer erkrankung |
| CR20180589A (es) | 2016-05-13 | 2019-02-27 | 4D Molecular Therapeutics Inc | Cápsulas variantes de virus adenoasociados y métodos de uso de estas |
| EP3458589A4 (de) | 2016-05-18 | 2020-01-01 | Voyager Therapeutics, Inc. | Zusammensetzungen und verfahren zur behandlung von morbus huntington |
| EP3458588B1 (de) | 2016-05-18 | 2025-10-29 | Voyager Therapeutics, Inc. | Modulatorische polynukleotide |
| KR102425289B1 (ko) | 2016-08-15 | 2022-07-27 | 젠자임 코포레이션 | Aav의 검출 방법 |
| CA3035522A1 (en) | 2016-08-30 | 2018-03-08 | The Regents Of The University Of California | Methods for biomedical targeting and delivery and devices and systems for practicing the same |
| EP3528785A4 (de) * | 2016-10-19 | 2020-12-02 | Adverum Biotechnologies, Inc. | Modifizierte aav-kaspide und verwendungen davon |
| BR112019016769A2 (pt) * | 2017-02-15 | 2020-05-26 | The University Of North Carolina At Chapel Hill | Métodos e composições para transferência genética através da vasculatura |
| CN110392607A (zh) * | 2017-03-13 | 2019-10-29 | 三菱化学株式会社 | 过渡金属负载沸石和其制造方法以及氮氧化物净化用催化剂和其使用方法 |
| US10550405B2 (en) | 2017-03-15 | 2020-02-04 | The University Of North Carolina At Chapel Hill | Rational polyploid adeno-associated virus vectors and methods of making and using the same |
| CN110770346B (zh) * | 2017-03-15 | 2024-01-12 | 北卡罗来纳-查佩尔山大学 | 多倍体腺相关病毒载体及其制备和使用方法 |
| US11752181B2 (en) | 2017-05-05 | 2023-09-12 | Voyager Therapeutics, Inc. | Compositions and methods of treating Huntington's disease |
| AU2018261790B2 (en) | 2017-05-05 | 2024-10-03 | Voyager Therapeutics, Inc. | Compositions and methods of treating amyotrophic lateral sclerosis (ALS) |
| JOP20190269A1 (ar) | 2017-06-15 | 2019-11-20 | Voyager Therapeutics Inc | بولي نوكليوتيدات aadc لعلاج مرض باركنسون |
| EP3654860A1 (de) | 2017-07-17 | 2020-05-27 | Voyager Therapeutics, Inc. | Trajektoriearrayführungssystem |
| EP4218828A3 (de) | 2017-09-20 | 2023-09-27 | 4D Molecular Therapeutics Inc. | Kapside mit adeno-assoziierten virenvarianten und verfahren zur verwendung davon |
| US20200263199A1 (en) | 2017-09-29 | 2020-08-20 | Voyager Therapeutics, Inc. | Rescue of central and peripheral neurological phenotype of friedreich's ataxia by intravenous delivery |
| WO2019079240A1 (en) | 2017-10-16 | 2019-04-25 | Voyager Therapeutics, Inc. | TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) |
| EP3697908A1 (de) | 2017-10-16 | 2020-08-26 | Voyager Therapeutics, Inc. | Behandlung von amyotropher lateralsklerose (als) |
| KR102793696B1 (ko) | 2017-11-27 | 2025-04-09 | 4디 몰레큘러 테라퓨틱스 아이엔씨. | 아데노-관련 바이러스 변이체 캡시드 및 혈관 신생을 억제하기 위한 용도 |
| JP2021514207A (ja) * | 2018-02-15 | 2021-06-10 | ビョークルン，トマス | 改変ウイルスカプシド |
| CN112272672A (zh) | 2018-04-03 | 2021-01-26 | 斯特里迪比奥公司 | 抗体逃避性病毒载体 |
| SG11202009450SA (en) | 2018-04-03 | 2020-10-29 | Stridebio Inc | Virus vectors for targeting ophthalmic tissues |
| SG11202009451VA (en) | 2018-04-03 | 2020-10-29 | Stridebio Inc | Antibody-evading virus vectors |
| CN110691846A (zh) * | 2018-05-07 | 2020-01-14 | 北卡罗来纳-查佩尔山大学 | 合理的多倍体腺相关病毒载体及其制造和使用方法 |
| CN112424359A (zh) | 2018-05-15 | 2021-02-26 | 沃雅戈治疗公司 | 用于治疗帕金森氏病的组合物和方法 |
| US11821009B2 (en) | 2018-05-15 | 2023-11-21 | Cornell University | Genetic modification of the AAV capsid resulting in altered tropism and enhanced vector delivery |
| GB201813528D0 (en) | 2018-08-20 | 2018-10-03 | Ucl Business Plc | Factor IX encoding nucleotides |
| US10842885B2 (en) | 2018-08-20 | 2020-11-24 | Ucl Business Ltd | Factor IX encoding nucleotides |
| EP3841109A4 (de) * | 2018-08-21 | 2022-09-21 | Massachusetts Eye and Ear Infirmary | Zusammensetzungen und verfahren zur modulation der transduktionseffizienz von adeno-assoziierten viren |
| CN113383010B (zh) | 2018-09-28 | 2025-09-09 | 沃雅戈治疗公司 | 具有经工程化改造的启动子的共济蛋白表达构建体及其使用方法 |
| CN113677801A (zh) | 2019-02-25 | 2021-11-19 | 诺华股份有限公司 | 治疗bietti晶体营养不良的组合物和方法 |
| WO2020174369A2 (en) | 2019-02-25 | 2020-09-03 | Novartis Ag | Compositions and methods to treat bietti crystalline dystrophy |
| SG11202110146VA (en) | 2019-03-21 | 2021-10-28 | Stridebio Inc | Recombinant adeno-associated virus vectors |
| US20210082541A1 (en) * | 2019-08-31 | 2021-03-18 | Wyatt Technology Corporation | Measuring attributes of a viral gene delivery vehicle sample via separation |
| US20230392163A1 (en) | 2019-10-17 | 2023-12-07 | Ginkgo Bioworks Inc. | Adeno-associated viral vectors for treatment of niemann-pick disease type c |
| CN116745409A (zh) | 2020-08-19 | 2023-09-12 | 萨雷普塔治疗公司 | 用于治疗雷特综合征的腺相关病毒载体 |
| EP4228610A1 (de) | 2020-10-13 | 2023-08-23 | Kriya Therapeutics, Inc. | Virale vektorkonstrukte zur abgabe von cytokin-codierenden nukleinsäuren und verwendungen davon zur behandlung von krebs |
| WO2024006433A1 (en) * | 2022-06-30 | 2024-01-04 | Carnegie Mellon University | Method for production of virus-like particles for gene delivery |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0702722B1 (de) * | 1993-06-07 | 2005-08-03 | Vical Incorporated | Für die gentherapie verwendbare plasmide |
| US6204059B1 (en) * | 1994-06-30 | 2001-03-20 | University Of Pittsburgh | AAV capsid vehicles for molecular transfer |
| US5741683A (en) * | 1995-06-07 | 1998-04-21 | The Research Foundation Of State University Of New York | In vitro packaging of adeno-associated virus DNA |
| EP0933997A4 (de) * | 1996-09-06 | 2000-08-16 | Chiron Corp | Verfahren und zusammensetzungen für die leberspezifische verabreichung von therapeutischen molekülen unter verwendung rekombinanter aav vektoren |
| US6221646B1 (en) * | 1997-07-31 | 2001-04-24 | Chiron Corporation | Materials and methods for simplified AAV production |
| CA2367375A1 (en) | 1999-03-15 | 2000-09-21 | Chiron Corporation | Use of recombinant gene delivery vectors for treating or preventing diseases of the eye |
| US6943153B1 (en) * | 1999-03-15 | 2005-09-13 | The Regents Of The University Of California | Use of recombinant gene delivery vectors for treating or preventing diseases of the eye |
| US6329181B1 (en) * | 2000-08-07 | 2001-12-11 | Neurologix, Inc. | Helper functions for recombinant vector production |
| WO2002024234A2 (en) | 2000-09-20 | 2002-03-28 | The Regents Of The University Of California | Use of recombinant gene delivery vectors for treating or preventing diseases of the eye |
| US6962815B2 (en) * | 2001-01-05 | 2005-11-08 | Children's Hopital Inc. | AAV2 vectors and methods |
| US6692815B2 (en) * | 2001-06-15 | 2004-02-17 | Vinylex Corporation | Extruded plastic lumber and method of manufacture |
| US6723551B2 (en) * | 2001-11-09 | 2004-04-20 | The United States Of America As Represented By The Department Of Health And Human Services | Production of adeno-associated virus in insect cells |
| AU2003221733A1 (en) * | 2002-04-17 | 2003-11-03 | University Of Florida Research Foundation, Inc. | Improved raav vectors |
| DE60323078D1 (de) | 2002-05-01 | 2008-10-02 | Univ Florida | Verbesserte raav-expressionssysteme für die genetische modifikation spezifischer capsidproteine |
| WO2004020600A2 (en) * | 2002-08-28 | 2004-03-11 | University Of Florida | Modified aav |
| EP1618201A1 (de) | 2003-05-01 | 2006-01-25 | University of Florida Research Foundation, Inc. | Vp2-modifizierte raav-vektoren und verwendungen davon |
-
2003
- 2003-05-01 DE DE60323078T patent/DE60323078D1/de not_active Expired - Fee Related
- 2003-05-01 NZ NZ536274A patent/NZ536274A/en unknown
- 2003-05-01 SI SI200331424T patent/SI1496944T1/sl unknown
- 2003-05-01 AT AT03786493T patent/ATE405295T1/de not_active IP Right Cessation
- 2003-05-01 DK DK03786493T patent/DK1496944T3/da active
- 2003-05-01 US US10/513,059 patent/US8802080B2/en active Active
- 2003-05-01 AU AU2003295312A patent/AU2003295312B2/en not_active Ceased
- 2003-05-01 EP EP03786493A patent/EP1496944B1/de not_active Expired - Lifetime
- 2003-05-01 NZ NZ561656A patent/NZ561656A/en unknown
- 2003-05-01 CA CA002483624A patent/CA2483624A1/en not_active Abandoned
- 2003-05-01 WO PCT/US2003/013583 patent/WO2004027019A2/en not_active Ceased
-
2014
- 2014-07-08 US US14/326,293 patent/US20150005369A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1496944A4 (de) | 2006-03-22 |
| EP1496944A2 (de) | 2005-01-19 |
| US20150005369A1 (en) | 2015-01-01 |
| AU2003295312B2 (en) | 2008-08-14 |
| EP1496944B1 (de) | 2008-08-20 |
| DE60323078D1 (de) | 2008-10-02 |
| WO2004027019A2 (en) | 2004-04-01 |
| HK1071518A1 (en) | 2005-07-22 |
| WO2004027019A3 (en) | 2004-08-05 |
| NZ561656A (en) | 2009-03-31 |
| SI1496944T1 (sl) | 2009-02-28 |
| CA2483624A1 (en) | 2004-04-01 |
| US20060088936A1 (en) | 2006-04-27 |
| AU2003295312A1 (en) | 2004-04-08 |
| DK1496944T3 (da) | 2008-12-01 |
| US8802080B2 (en) | 2014-08-12 |
| NZ536274A (en) | 2008-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60323078D1 (de) | Verbesserte raav-expressionssysteme für die genetische modifikation spezifischer capsidproteine | |
| MY199445A (en) | Adeno-associated virus variant capsids and methods of use thereof | |
| TW202102525A (zh) | 重組腺相關病毒載體 | |
| WO2005077333A3 (en) | Gel-based delivery of recombinant adeno-associated virus vectors | |
| WO2005005610A3 (en) | Mutant adeno-associated virus virions and methods of use thereof | |
| DK1783225T3 (da) | Strukturprotein fra AAV, dets fremstilling og anvendelse | |
| DE60033293D1 (de) | Neue b7-4 moleküle und deren verwendungen | |
| ATE360031T1 (de) | Chimäre proteine und anwendungen | |
| WO2003088899A3 (en) | Methods for the production of chimeric adeno-associated virus (aav) vectors, compositions of chimeric aav vectors, and methods of use thereof | |
| DE60031418D1 (de) | 15571, ein neues gpcr-ähnliches molekül der secretin-ähnlichen familie und dessen verwendungen | |
| ATE480620T1 (de) | Neue pgc-1-isoformen und deren verwendungen | |
| WO2002002148A3 (en) | Dual recombinant gene therapy compositions and methods of use | |
| WO2001083781A3 (en) | 14094, a novel human trypsin family member and uses thereof | |
| DK1664315T3 (da) | AAV-vektorer til in vivo genterapi af rheumatoid arthritis | |
| WO2001073074A3 (en) | 18806, a novel trypsin serine protease-like molecule and uses thereof | |
| WO2001064894A3 (en) | Human phospholipid scramblase-like molecules and uses thereof | |
| ATE476194T1 (de) | Ein mitglied der menschlichen proteinkinasefamilie, und verwendungen dafür | |
| ATE445714T1 (de) | 15603, ein mitglied der humanen ionenkanal- familie | |
| WO2003035840A3 (en) | 69583 and 85924, novel human protein kinase family members and uses therefor | |
| DE60136832D1 (de) | Atcr-1, eine humane acyltransferase und verwendungen davon | |
| WO2001068806A3 (en) | 26934, a novel cytidine deaminase-like molecule and uses thereof | |
| AU2001288284A1 (en) | 14189, a human kinase and uses thereof | |
| WO2001075098A3 (en) | 33166, a human hydrolase-like molecule and uses thereof | |
| WO2001090327A3 (en) | 21910, a membrane-associated guanylate kinase and uses thereof | |
| DE60120974D1 (de) | Proteinkinase-molekül 14911 und dessen anwendungen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |